Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer

Clinics

Volumn 68, Issue 5, 2013, Pages 686-693

  Jin, Ying ^a   Zhao, Li ^b   Peng, Fang ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG HOSPITAL   (China)

Author keywords

Prognostic Impact; Recurrence Free Survival; Serum Albumin Level; Stage I Non Small Cell Lung Cancer

Indexed keywords

SERUM ALBUMIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84878455602     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(05)17     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49, http://dx.doi.org/10.3322/caac. 20006.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 CA Cancer J Clin. 2012;62(1):10-29.
3. Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, et al. The adenocarcinoma-specific stage shift in the Anti-lung Cancer Association project: significance of repeated screening for lung cancer for more than 5 years with low-dose helical computed tomography in a high-risk cohort. Lung Cancer. 2010;67(3):318-24, http://dx.doi.org/10. 1016/j.lungcan.2009.04.016.
4. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109(1):120-9, http://dx.doi.org/10.1016/S0022-5223(95)70427-2.
5. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719-27, http://dx. doi.org/10.1016/S1470-2045(06)70804-X.
6. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-60.
7. Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RNC, Yang JCH, et al. Survival Following Surgery with or without Adjuvant Chemotherapy for Stage I-IIIA Non-Small Cell Lung Cancer: An East Asian Population-Based Study. Oncologist. 2012;17(10):1294-302, http://dx.doi.org/10. 1634/theoncologist.2012-0082.
8. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2007;13(2):73-7.
9. Diederich S. Lung cancer staging update: the revised TNM classification. Cancer Imaging. 2010;10 Spec no A:S134-5, http://dx.doi.org/10.1102/ 1470-7330.2010.9022.
10. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of MicroRNA Expression Profiles That May Predict Recurrence of Localized Stage I Non-Small Cell Lung Cancer after Surgical Resection. Cancer Res. 2010;70(1):36-45, http://dx.doi.org/10.1158/0008-5472.CAN-09-3153.
11. Starnes SL, Pathrose P, Wang J, Succop P, Morris JC, Bridges J, et al. Clinical and Molecular Predictors of Recurrence in Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2012;93(5):1606-13, http://dx.doi. org/10.1016/j.athoracsur.2012.01.048.
12. Lu Y, Wang L, Liu PY, Yang P, You M. Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients. Plos One. 2012;7(1):e30880, http://dx.doi.org/10.1371/ journal.pone.0030880.
13. Rinewalt D, Shersher DD, Daly S, Fhied C, Basu S, Mahon B, et al. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiov Sur. 2012;144(6):1344-51, http://dx.doi.org/10.1016/j.jtcvs.2012.08.033.
14. Wagner KW, Ye YQ, Lin J, Vaporciyan AA, Roth JA, Wu XF. Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2012;18(2):585-92, http://dx.doi.org/10.1158/1078-0432.CCR-11-2087.
15. Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A. Malnutrition among gynaecological cancer patients. Eur J Clin Nutr. 2007;61(5):642-6.
16. Fuhrman P, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. J Am Diet Assoc. 2004;104(8):1258-64, http://dx.doi.org/10. 1016/j.jada.2004.05.213.
17. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 2010;9:69, http://dx.doi.org/10.1186/1475-2891-9-69.
18. Franch-Arcas G. The meaning of hypoalbuminaemia in clinical practice. Clin Nutr. 2001;20(3):265-9, http://dx.doi.org/10.1054/clnu.2001.0438.
19. Law MR, Morris JK, Wald NJ, Hale AK. Serum-Albumin and Mortality in the Bupa Study. Int J Epidemiol. 1994;23(1):38-41.
20. Cengiz O, Kocer B, Surmeli S, Santicky MJ, Soran A. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monitor. 2006;12(6):Cr240-Cr7.
21. Boonpipattanapong T, Chewatanakornkul S. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol. 2006;40(7):592-5, http://dx.doi.org/10.1097/00004836-200608000-00006.
22. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381-9, http://dx.doi.org/10.1245/s10434-006-9093-x.
23. Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA. Is serum albumin an independent predictor of survival in patients with breast cancer? Jpen-Parenter Enter. 2003;27(1):10-5, http://dx.doi.org/10.1177/014860710 302700110.
24. Espinosa E, Feliu J, Zamora P, Baron MG, Sanchez JJ, Ordonez A, et al. Serum-Albumin and Other Prognostic Factors Related to Response and Survival in Patients with Advanced Nonsmall Cell Lung-Cancer. Lung Cancer. 1995;12(1-2):67-76, http://dx.doi.org/10.1016/0169-5002(95)00407-R.
25. Peters T. Serum-Albumin. Adv Protein Chem. 1985;37:161-245, http:// dx.doi.org/10.1016/S0065-3233(08)60065-0.
26. Hung JJ, Jeng WJ, Hsu WH, Huang BS, Wu YC. Time Trends of Overall Survival and Survival after Recurrence in Completely Resected Stage I Non-small Cell Lung Cancer. J Thorac Oncol. 2012;7(2):397-405, http:// dx.doi.org/10.1097/JTO.0b013e31823b564a.
27. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, DeCamp MM. Varying Recurrence Rates and Risk Factors Associated With Different Definitions of Local Recurrence in Patients With Surgically Resected, Stage I Nonsmall Cell Lung Cancer. Cancer-Am Cancer Soc. 2010;116(10):2390-400.
28. Flores RM, Ihekweazu UN, Rizk N, Dycoco J, Bains MS, Downey RJ, et al. Patterns of recurrence and incidence of second primary tumors after lobectomy by means of video-assisted thoracoscopic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiov Sur. 2011;141(1):59-64, http://dx.doi.org/10.1016/j.jtcvs.2010.08.062.
29. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-51, http://dx.doi.org/10.1200/JCO.2008.16.4855.
30. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552-9, http://dx.doi.org/10.1200/JCO.2007.13.9030.
31. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis. 1998;32(6 Suppl 4):S118-25, http://dx.doi. org/10.1016/S0272-6386(98)70174-X.
32. Lohsiriwat V, Lohsiriwat D, Boonnuch W, Chinswangwatanakul V, Akaraviputh T, Lert-Akayamanee N. Pre-operative hypoalbuminemia is a major risk factor for postoperative complications following rectal cancer surgery. World J Gastroentero. 2008;14(8):1248-51.
33. Asher V, Lee J, Bali A. Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer. Med Oncol. 2012;29(3):2005-9, http://dx.doi.org/10.1007/s12032-011-0019-5.
34. Win T, Sharples L, Groves AM, Ritchie AJ, Wells FC, Laroche CM. Predicting survival in potentially curable lung cancer patients. Lung. 2008;186(2):97-102, http://dx.doi.org/10.1007/s00408-007-9067-1.
35. Maeda T, Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, et al. Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol. 2000;30(12):534-41.
36. Fujii T, Sutoh T, Morita H, Katoh T, Yajima R, Tsutsumi S, et al. Serum Albumin Is Superior to Prealbumin for Predicting Short-Term Recurrence in Patients with Operable Colorectal Cancer. Nutr Cancer. 2012;64(8):1169-73, http://dx.doi.org/10.1080/01635581.2012.718034.
37. O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer. 1998;32(2):76-80, http://dx.doi.org/10. 1080/01635589809514722.
38. Barber MD, Ross JA, Fearon KCH. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 1999;35(2):106-10, http://dx.doi.org/10.1207/S15327914NC352_ 2.
39. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210-3, http://dx.doi.org/10.1207/ S15327914nc392_8.